Robert W. Baird Cuts AdaptHealth (NASDAQ:AHCO) Price Target to $14.00

AdaptHealth (NASDAQ:AHCO) had its target price reduced by Robert W. Baird from $16.00 to $14.00 in a report issued on Wednesday morning,Benzinga reports. They currently have an outperform rating on the stock.

Separately, Royal Bank of Canada reissued an “outperform” rating and issued a $13.00 price objective on shares of AdaptHealth in a research note on Monday, August 12th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, AdaptHealth has a consensus rating of “Moderate Buy” and a consensus target price of $12.17.

AdaptHealth Stock Performance

AdaptHealth stock opened at $10.09 on Wednesday. The company has a 50 day moving average price of $10.70 and a 200-day moving average price of $10.44. The company has a debt-to-equity ratio of 1.34, a quick ratio of 0.94 and a current ratio of 1.24. AdaptHealth has a fifty-two week low of $6.43 and a fifty-two week high of $11.90. The company has a market capitalization of $1.36 billion, a PE ratio of -6.12, a P/E/G ratio of 1.58 and a beta of 1.11.

AdaptHealth (NASDAQ:AHCO) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.15 EPS for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.02). The business had revenue of $805.90 million during the quarter, compared to the consensus estimate of $809.32 million. AdaptHealth had a positive return on equity of 9.62% and a negative net margin of 6.57%. The business’s quarterly revenue was up .2% on a year-over-year basis. During the same period last year, the firm earned $0.19 EPS. As a group, equities analysts forecast that AdaptHealth will post 0.87 earnings per share for the current year.

Insider Transactions at AdaptHealth

In other news, Director David Solomon Williams III sold 4,000 shares of the company’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $11.26, for a total transaction of $45,040.00. Following the transaction, the director now directly owns 36,899 shares of the company’s stock, valued at approximately $415,482.74. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Director David Solomon Williams III sold 4,000 shares of the business’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $11.26, for a total transaction of $45,040.00. Following the sale, the director now directly owns 36,899 shares of the company’s stock, valued at $415,482.74. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Shaw Rietkerk sold 25,000 shares of the business’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of $11.24, for a total transaction of $281,000.00. Following the sale, the chief operating officer now directly owns 212,611 shares in the company, valued at $2,389,747.64. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.43% of the company’s stock.

Institutional Investors Weigh In On AdaptHealth

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in AdaptHealth by 8.9% in the first quarter. Vanguard Group Inc. now owns 10,017,722 shares of the company’s stock valued at $115,304,000 after purchasing an additional 818,241 shares during the last quarter. Reinhart Partners LLC. boosted its holdings in AdaptHealth by 45.2% in the third quarter. Reinhart Partners LLC. now owns 6,198,642 shares of the company’s stock valued at $69,611,000 after purchasing an additional 1,929,339 shares during the last quarter. Segall Bryant & Hamill LLC boosted its holdings in AdaptHealth by 15.5% in the third quarter. Segall Bryant & Hamill LLC now owns 3,701,808 shares of the company’s stock valued at $41,571,000 after purchasing an additional 496,453 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in AdaptHealth by 43.9% in the second quarter. Dimensional Fund Advisors LP now owns 2,327,738 shares of the company’s stock valued at $23,277,000 after purchasing an additional 710,131 shares during the last quarter. Finally, Divisadero Street Capital Management LP boosted its holdings in AdaptHealth by 179.7% in the second quarter. Divisadero Street Capital Management LP now owns 1,161,592 shares of the company’s stock valued at $11,616,000 after purchasing an additional 746,340 shares during the last quarter. 82.67% of the stock is owned by hedge funds and other institutional investors.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.